EU research results


English EN
Making a yeast-based candidate vaccine against Porcine Epidemic Diarrhea Virus  (PEDV)

Making a yeast-based candidate vaccine against Porcine Epidemic Diarrhea Virus (PEDV)


PIGYVAX aims to create pig vaccine candidates against PEDV, a pathogen of swine causing significant challenges to the swine industry globally. This project will utilize yeast-based vaccine carrying nanoparticles of measles ribonucleoprotein (RNP) fused with PEDV spike protein (S1). The multimerization of monomeric S1 antigen through RNP will increase immunogenicity due to better recognition of antigen presenting cells. As the yeast delivery system has strong auto-adjuvant properties, the vaccine does not require complementation with accessory adjuvant, which reduces the cost of vaccine production. Moreover, P. pastoris yeast, commonly present on fruits, is a certified safe microorganism for animal feeds rendering it a most practical and convenient way to deliver vaccines to large-scale farms. Therefore, we aim to use this vaccine platform to express S1 antigen of PEDV and deliver it orally to stimulate a protective immune response against PEDV in sows, which will be passively transferred to fully protect piglets from succumbing to the disease. In this project, Dr. Phanramphoei Frantz will utilize her knowledge on pathogenesis of PEDV and the yeast-RNP platform while gaining expertise on vaccine study and development from the host institute. This will initiate a successful collaboration project between Institut Pasteur and BIOTEC (Thailand) to where the experienced researcher will return after the project.




Rue Du Docteur Roux 25-28
75724 Paris Cedex 15


Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 185 076

Project information

Grant agreement ID: 707128


Closed project

  • Start date

    13 June 2016

  • End date

    12 June 2018

Funded under:


  • Overall budget:

    € 185 076

  • EU contribution

    € 185 076

Coordinated by: